Loading
companiesCompany
Elypta
Elypta, of Stockholm, measures glycosaminoglycans, sugar molecules in blood and urine, and scores them with machine learning to detect kidney cancer returning after surgery; a second programme tests whether the same signature can flag any cancer early in symptom-free adults. Only interim data support the screening use.
Overview
Elypta, based in Solna, Stockholm, has developed a metabolism-based liquid biopsy that profiles the glycosaminoglycan (GAG) composition of blood and urine (the GAGome), using its MIRAM kit and machine-learning scores to detect cancer-specific signatures; the company is ISO 13485 certified. Its first application is recurrence monitoring after kidney cancer surgery: the AURORAX programme, described as the largest such study, reached study end in May 2025. A second programme applies GAGome scores to multi-cancer early detection in asymptomatic adults, with interim data suggesting urine GAGs may predict risk of any cancer. Funding includes a EUR 2.35 million Horizon 2020 grant (2019), a EUR 6.1 million late seed led by Industrifonden (2020), a $21 million Series A led by Bonnier Ventures (2022) and a $1 million Roddenberry prize (2023).
Headquarters
Stockholm, SE
Funding
All startupsStartup
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Series A · Led by Bonnier Ventures, June 2022. | 2022 | $21M | elypta.com |
| Seed · EUR 6.1 million late seed round led by Industrifonden, January 2020 (as listed on the company news page). | 2020 | undisclosed | elypta.com |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Startup
Website
Notes
top- Founding year not stated (earliest news item is July 2017). The Horizon 2020 grant and Roddenberry prize are described on the news listing page but not recorded as rounds because their individual pages were not fetched.
Similar pages
- CompanyVolitionRx
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- CompanyNumen
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- CompanyClearNote Health
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- IdeaCheap DNA fragment-pattern blood test as a first sieve before expensive cancer tests
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- CompanyExai Bio
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- TechnologyBreath and volatile-organic-compound detection
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- IdeaBank yearly blood from cancer survivors so future tests can be validated
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).
- IdeaMandatory interval-cancer audit for every blood-based screening test
Shares Multi-cancer early detection (MCED), Liquid biopsy (ctDNA).